JONES WILLIAM A JR
Insider CIK 1373097 · ANNX Director · BHVN CCO-Migraine & Common Disease · APMD Director · AKLI Director · NAMS Chief Commercial Officer · APGE Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 34,824 | — | $0 | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 7,657 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 14,461 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer deriv | 2026-09-03 | 2026-09-03 | 10,370 | — | — | 0 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | D To issuer | 2026-09-03 | 2026-09-03 | 34,824 | — | — | 0 | SEC↗ |
| APMD Apnimed, Inc. | A Award deriv | 2026-08-03 | 2026-08-03 | 44,477 | — | $0 | 44,477 | SEC↗ |
| APMD Apnimed, Inc. | D To issuer deriv | 2026-08-03 | 2026-08-03 | 44,477 | — | $0 | 0 | SEC↗ |
| APMD Apnimed, Inc. | A Award deriv | 2026-08-03 | 2026-08-03 | 44,477 | — | $0 | 44,477 | SEC↗ |
| APMD Apnimed, Inc. | D To issuer deriv | 2026-08-03 | 2026-08-03 | 44,477 | — | $0 | 0 | SEC↗ |
| APMD Apnimed, Inc. | A Award deriv | 2026-07-30 | 2026-08-03 | 44,477 | — | $0 | 44,477 | SEC↗ |
| APMD Apnimed, Inc. | A Award deriv | 2026-07-30 | 2026-08-03 | 44,477 | — | $0 | 44,477 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2026-06-11 | 2026-06-15 | 65,000 | — | $0 | 65,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2026-06-09 | 2026-06-11 | 7,657 | — | $0 | 7,657 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2025-06-17 | 2025-06-20 | 14,461 | — | $0 | 14,461 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2025-06-05 | 2025-06-09 | 55,000 | — | $0 | 55,000 | SEC↗ |
| ANNX Annexon, Inc. | A Award deriv | 2025-01-09 | 2025-01-10 | 88,000 | — | $0 | 88,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award | 2025-01-07 | 2025-01-07 | 43,000 | — | $0 | 43,000 | SEC↗ |
| NAMS NewAmsterdam Pharma Co N.V | A Award deriv | 2025-01-02 | 2025-01-06 | 200,000 | — | $0 | 200,000 | SEC↗ |
| APGE Apogee Therapeutics, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 10,370 | — | $0 | 10,370 | SEC↗ |
| AKLI Akili, Inc. | A Award deriv | 2023-05-02 | 2023-05-04 | 22,000 | — | $0 | 22,000 | SEC↗ |
| AKLI Akili, Inc. | A Award deriv | 2022-11-02 | 2022-11-04 | 44,000 | — | $0 | 44,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 29,225 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 775 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 3,000 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 10,000 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 11,250 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 44,087 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 2,398 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 37,602 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 1,742 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 5,913 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer deriv | 2022-10-03 | 2022-10-03 | 28,258 | — | $0 | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | D To issuer | 2022-10-03 | 2022-10-03 | 14,226 | $148.50 | $2.11M | 0 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2022-01-07 | 2022-01-07 | 15,000 | — | $0 | 15,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2022-01-07 | 2022-01-07 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2022-01-07 | 2022-01-07 | 3,750 | — | $0 | 11,250 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2022-01-07 | 2022-01-07 | 3,750 | — | $0 | 15,630 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2022-01-07 | 2022-01-07 | 1,631 | $128.87 | $210.2K | 13,999 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2022-01-06 | 2022-01-07 | 5,000 | — | $0 | 10,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2022-01-06 | 2022-01-07 | 5,000 | — | $0 | 14,110 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2022-01-06 | 2022-01-07 | 2,230 | $123.86 | $276.2K | 11,880 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2021-11-25 | 2021-11-26 | 3,000 | — | $0 | 3,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2021-11-25 | 2021-11-26 | 3,000 | — | $0 | 10,127 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2021-11-25 | 2021-11-26 | 1,305 | $115.55 | $150.8K | 8,822 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2021-01-06 | 2021-01-08 | 20,000 | — | $0 | 20,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2021-01-06 | 2021-01-08 | 40,000 | — | $0 | 40,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2021-01-06 | 2021-01-08 | 5,000 | — | $0 | 15,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2021-01-06 | 2021-01-08 | 2,124 | $83.38 | $177.1K | 7,127 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2021-01-06 | 2021-01-08 | 5,000 | — | $0 | 9,251 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2020-11-25 | 2020-11-27 | 3,000 | — | $0 | 6,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2020-11-25 | 2020-11-27 | 3,000 | — | $0 | 4,755 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2020-11-25 | 2020-11-27 | 1,245 | $90.14 | $112.2K | 3,510 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2020-11-02 | 2020-11-04 | 30,000 | — | $0 | 50,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | S Sale | 2020-11-02 | 2020-11-04 | 1,300 | $77.70 | $101.0K | 1,755 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2020-11-02 | 2020-11-04 | 30,000 | $50.72 | $1.52M | 31,755 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | S Sale | 2020-11-02 | 2020-11-04 | 4,010 | $77.01 | $308.8K | 3,055 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | S Sale | 2020-11-02 | 2020-11-04 | 24,690 | $76.02 | $1.88M | 7,065 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise deriv | 2019-12-18 | 2019-12-20 | 3,000 | — | $0 | 9,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | F Tax w/h | 2019-12-18 | 2019-12-20 | 1,245 | $52.13 | $64.9K | 1,755 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | M Exercise | 2019-12-18 | 2019-12-20 | 3,000 | — | $0 | 3,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2019-11-25 | 2019-11-27 | 12,000 | — | $0 | 12,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2019-11-25 | 2019-11-27 | 30,000 | — | $0 | 30,000 | SEC↗ |
| BHVN Biohaven Pharmaceutical Ho | A Award deriv | 2019-04-01 | 2019-04-03 | 80,000 | — | $0 | 80,000 | SEC↗ |